FS 102
Alternative Names: BMS-986186; BMS-986186-01; FS102Latest Information Update: 07 Jun 2023
At a glance
- Originator f-star
- Developer F-star Therapeutics
- Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoglobulin Fc fragments; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gastric cancer; HER2 positive breast cancer; Solid tumours
Most Recent Events
- 31 May 2023 Selexis has merged with KBI Biopharma to form KBI Biopharma
- 09 Mar 2023 F-star Therapeutics has been acquired by invoX Pharma
- 28 Jan 2023 No recent reports of development identified for phase-I development in Gastric-cancer(Late-stage disease, Second-line therapy or greater) in Canada (IV, Infusion)